Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Development and characterization of a chronic hepatitis B murine model with a mutation in the START codon of an HBV polymerase

L. Vanekova, M. Polidarova, V. Charvat, Z. Vavrina, V. Veverka, G. Birkus, A. Brazdova

. 2023 ; 72 (1) : 37-47. [pub] 20221222

Language English Country Czech Republic

Document type Journal Article

Chronic hepatitis B (CHB) is caused by the Hepatitis B virus (HBV) and affects millions of people worldwide. Developing an effective CHB therapy requires using in vivo screening methods, such as mouse models reflecting CHB based on hydrodynamic delivery of plasmid vectors containing a replication-competent HBV genome. However, long-term expression of HBV proteins is accompanied by production of progeny virions, thereby requiring a Biosafety Level (BSL) 3 animal facility. In the present study, we introduced a point mutation in the START codon of the HBV polymerase to develop a mouse model reflecting chronic hepatitis B infection without formation of viral progeny. We induced the mouse model by hydrodynamic injection of adeno-associated virus plasmid vector (pAAV) and minicircle plasmid (pMC) constructs into C57Bl/6 and C3H/HeN mouse strains, monitoring HBV antigens and antibodies in blood by enzyme-linked immunosorbent assay and analyzing liver expression of HBV core antigen by immunohistology. Persisting expression of viral antigens over 140 days (study endpoint) was observed only in the C3H/HeN mouse strain when using pAAV/1.2HBV-A and pMC/1.0HBV-D with pre-C and pre-S recombination sites. In addition, pAAV/1.2HBV-A in C3H/HeN sustained HBV core antigen positivity up to the study endpoint in C3H/HeN mice. Moreover, introducing the point mutation in the START codon of polymerase effectively prevented the formation of viral progeny. Our study establishes an accessible and affordable experimental paradigm for developing a robust mouse model reflecting CHB suitable for preclinical testing of anti-HBV therapeutics in a BSL2 animal facility.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002226
003      
CZ-PrNML
005      
20230519084807.0
007      
ta
008      
230406s2023 xr da f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934979 $2 doi
035    __
$a (PubMed)36545874
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Vanekova, Lenka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
245    10
$a Development and characterization of a chronic hepatitis B murine model with a mutation in the START codon of an HBV polymerase / $c L. Vanekova, M. Polidarova, V. Charvat, Z. Vavrina, V. Veverka, G. Birkus, A. Brazdova
520    9_
$a Chronic hepatitis B (CHB) is caused by the Hepatitis B virus (HBV) and affects millions of people worldwide. Developing an effective CHB therapy requires using in vivo screening methods, such as mouse models reflecting CHB based on hydrodynamic delivery of plasmid vectors containing a replication-competent HBV genome. However, long-term expression of HBV proteins is accompanied by production of progeny virions, thereby requiring a Biosafety Level (BSL) 3 animal facility. In the present study, we introduced a point mutation in the START codon of the HBV polymerase to develop a mouse model reflecting chronic hepatitis B infection without formation of viral progeny. We induced the mouse model by hydrodynamic injection of adeno-associated virus plasmid vector (pAAV) and minicircle plasmid (pMC) constructs into C57Bl/6 and C3H/HeN mouse strains, monitoring HBV antigens and antibodies in blood by enzyme-linked immunosorbent assay and analyzing liver expression of HBV core antigen by immunohistology. Persisting expression of viral antigens over 140 days (study endpoint) was observed only in the C3H/HeN mouse strain when using pAAV/1.2HBV-A and pMC/1.0HBV-D with pre-C and pre-S recombination sites. In addition, pAAV/1.2HBV-A in C3H/HeN sustained HBV core antigen positivity up to the study endpoint in C3H/HeN mice. Moreover, introducing the point mutation in the START codon of polymerase effectively prevented the formation of viral progeny. Our study establishes an accessible and affordable experimental paradigm for developing a robust mouse model reflecting CHB suitable for preclinical testing of anti-HBV therapeutics in a BSL2 animal facility.
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    12
$a chronická hepatitida B $x genetika $7 D019694
650    _2
$a kodon iniciační $7 D018387
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a myši inbrední C3H $7 D008809
650    _2
$a virus hepatitidy B $x genetika $7 D006515
650    _2
$a mutace $7 D009154
655    _2
$a časopisecké články $7 D016428
700    1_
$a Polidarova, Marketa $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Charvat, Vilem $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vavrina, Zdenek $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Veverka, Václav, $d 1973- $7 xx0301322 $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Birkuš, Gabriel, $d 1972- $7 xx0301324 $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Brázdová, Andrea $7 ntk2015859863 $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 72, č. 1 (2023), s. 37-47
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36545874 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20230406 $b ABA008
991    __
$a 20230519084800 $b ABA008
999    __
$a ok $b bmc $g 1933554 $s 1188432
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 72 $c 1 $d 37-47 $e 20221222 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK198 $a Pubmed-20230406

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...